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ABSTRACT
The clinical and epidemiological importance of chronic B hepatitis is currently unquestionable as a 
cause of end-stage liver disease and hepatocellular carcinoma. Recently, predictors of treatment re-
sponse of this disease have been studied, both before and during the course of medication. Therapy 
stopping rules have been proposed, which may be useful in patients presenting poor treatment tol-
erance. This review discusses the treatment response predictors usefulness, with emphasis on ALT, 
quantitative HBsAg and HBeAg, quantitative HBV-DNA and HBV genotype.
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INTRODUCTION
Infection by hepatitis B virus (HBV) is a global 
health problem, which currently affects around 
400 million people worldwide. It is estimated 
that more than 200,000 to 300,000 patients with 
chronic hepatitis B die annually due to liver cir-
rhosis and hepatocellular carcinoma, respective-
ly.1 Persistent viral replication is associated with 
disease progression. As a consequence, antiviral 
therapy must achieve maximal suppression to 
improve the clinical outcome. As no antiviral 
treatment is perfect, it is advantageous to evaluate 
response prediction factors to modify the thera-
peutic regimen according to these indications.2
As liver complications occur over dec-
ades, most therapeutic studies use short-
term surrogate response markers. To evaluate 
predictors of treatment response, one must 
understand the meaning and the importance 
of each of these markers. Moreover, the re-
sponse during treatment with nucleotide ana-
logs (NA) must be clearly differentiated from 
the response achieved after treatment with 
pegylated interferon (PEG-IFN). 
Long-term evolution markers 
Elimination of the hepatitis B surface 
antigen (HBsAg)
Elimination of HBsAg, with or without 
the development of anti-HBs antibody, is 
considered the criterion for HBV infection 
resolution and, probably, the best defini-
tion for virological response.3-5 Longitudi-
nal studies have demonstrated that HBsAg 
serological disappearance represents an ex-
cellent long-term prognosis, given that the 
loss of HBsAg occurs in younger individuals 
(< 50 years) and prevents the development 
of advanced fibrosis and cirrhosis.6 Unfor-
tunately, it seldom occurs, either spontane-
ously or after antiviral treatment. In general, 
HBsAg disappearance is a sustained event, 
except when the patient becomes immuno-
suppressed. However, a German study dem-
onstrated that HBsAg can reappear after 
treatment discontinuation with pegylated 
interferon, in spite of the maintenance of 
treatment with adefovir.7
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Seroconversion of antigen e of hepatitis B virus 
(HBeAg)
In HBeAg-positive patients with chronic hepatitis B, 
disappearance of HBeAg and seroconversion for anti-
HBe is usually considered a satisfactory outcome during 
antiviral treatment.3-5 Disappearance of HBeAg, whether 
spontaneous or post-antiviral treatment, reduces the risk 
of hepatic impairment and increases survival.8-11 Never-
theless, 10%-30% of the patients can still present high 
ALT and high levels of HBV-DNA after HBeAg serocon-
version and 10%-20% of the inactive carriers may reac-
tivate HBV replication and have exacerbation of hepa-
titis after years of quiescence.12-14 Most hepatitis flares, 
after HBeAg seroconversion occur within six months 
after interferon therapy withdrawal, but can occur later, 
and even a few years after lamivudine withdrawal.15,16 As 
a consequence, seroconversion of HBeAg can be used as 
a response marker only when sustained for at least six 
months after the end of therapy, and may be the best 
marker for treatment with pegylated interferon com-
pared to NA. 
Viral suppression of HBV-DNA 
Many Asian prospective studies have demonstrated that 
a high level of HBV-DNA was an independent risk fac-
tor for the development of cirrhosis and hepatocellular 
carcinoma.17,18 Therefore, persistent suppression of the 
HBV-DNA, ideally at an undetectable level or, at least, 
at a level of 2,000 UI/mL (10,000 copies/mL), is another 
acceptable marker for treatment response. In studies 
that analyzed treatment with lamivudine in HBeAg-
negative patients or those with advanced liver fibrosis, 
sustained viral suppression was associated with the de-
crease in complications of cirrhosis and hepatocellular 
carcinoma.11,19,20 A recent meta-analysis showed that the 
risk of hepatocellular carcinoma can be significantly de-
creased with viral suppression through antiviral thera-
py.21 After NA withdrawal, relapse of viral infection can 
occur in most HBeAg-positive individuals that did not 
loose the HBeAg, as well as in HBeAg-negative individu-
als. The durability of drug induced viral suppression af-
ter a one-year treatment with lamivudine or adefovir in 
HBeAg patients has been < 10%.3,23 For HBeAg-negative 
patients that receive peginterferon, most who maintains 
HBV-DNA suppression < 2,000 UI/mL for one year after 
treatment, will sustain viral suppression up to the third 
year.24 Consequently, the use of HBV-DNA levels as a 
surrogate marker for treatment response is valid only if 
viral suppression is maintained during NA treatment. 
As for treatment with peginterferon of HBeAg-negative 
patients, the sustained suppression of the HBV-DNA up 
to one year after treatment is also a reasonable response 
marker.
Drug resistance
A peculiar characteristic of NA use is the possibility of 
drug resistance. The development of resistance can lead 
to viral escape, biochemical exacerbation, histological de-
terioration, hepatic decompensation, and increased risk 
of hepatic complications.11,25,26 Even though rescue treat-
ments are available for resistant cases, good viral suppres-
sion is not always attained.27,28 In addition to monitor 
the emergency of resistance, it is also recommended to 
identify patients with high risk of developing resistance 
during treatment, and modify the therapeutic regimen as 
soon as possible. 
Different measures of outcomes for treatment with 
peginterferon and NA
Sustained response versus maintained response
PEG-IFN and NA have different mechanisms of action. 
PEG-IFN has a predominantly immunomodulatory ef-
fect and poor antiviral activity. This double action results 
in the suppression of viral replication and disappearance 
of infected hepatocytes. NA has a potent antiviral effect 
through the inhibition of reverse transcriptase activity 
and HBV-DNA polymerase.29 Due to these intrinsic dif-
ferences between the classes of medications, PEG-INF can 
be administered for a limited time period, as it presents 
a more durable response after drug withdrawal. Differ-
ently, the NA are usually used for a long time, associated 
with lower response durability following treatment with-
drawal, even after HBeAg seroconversion or adequate 
suppression of HBV-DNA.3 As a consequence, different 
time points are used to assess treatment outcome. 
Sustained response – defined as persistent thera-
peutic response for a period after therapy discontinua-
tion – is more appropriate for treatment with PEG-IFN. 
This period is usually of 6 to 12 months and, sometimes, 
longer. Maintained response – defined as a response to 
persistent therapy throughout treatment up to the mo-
ment of assessment – is more appropriate for treatment 
with NA. For maintained response to be significant, it 
is preferable to count with longer treatment duration, 
probably for a few years, especially in the case of medi-
cations with a low genetic barrier to resistance. If the 
sustained response for NA is assessed, a longer period 
of observation after drug withdrawal is necessary, as re-
lapse can occur after the first year postreatment.16
Progression markers for PEG-IFN
The most commonly used marker to assess treatment 
progression with PEG-IFN is the sustained HBeAg sero-
conversion, which is usually assessed 6 to 12 months after 
the end of the treatment. In a long-term follow-up of a 
European multicentric study, 81% of the initial respond-
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ers (loss of HBeAg 6 months postreatment) remained 
HBeAg-negative, whereas 58% of the initial respond-
ers presented levels of HBV-DNA < 2,000 UI/mL, three 
years after treatment.30 Similarly, in a study conducted 
in Hong Kong, 46% of the initial responders remained 
HBeAg-negative and 29% presented levels of HBV-DNA 
< 5,000 UI/mL, three years after treatment.15
The sustained disappearance of HBsAg is a more com-
plete marker for viral suppression compared to the disap-
pearance of HBeAg. However, HBsAg clearance is a late 
event. Studies conducted in Europe and the USA have re-
ported that the late disappearance of HBsAg occurred in 
12%-65% of the patients, within five years of HBeAg loss, 
but it was rarely observed in among Asian patients.8,31-35 
Among patients who received a one-year treatment with 
PEG-IFN, 9%-11% lost HBsAg three years after the end 
of treatment.24,30 Therefore, predictors for disappearance 
of HBsAg during treatment are more important than 
those for seroconversion, but a longer-term follow-up is 
necessary for their assessment. 
Evolution markers for NA
The maintenance of viral suppression is the most com-
monly used indicator to measure the effectiveness of NA. 
As viral resistance can occur if there is persistent active 
viral replication, undetectable HBV-DNA by polymerase 
chain reaction (PCR) is required to prevent resistance to 
NA. In other words, although there is no evidence that sug-
gests that undetectable level of HBV-DNA is necessary for 
a better prognosis, levels of 2,000 UI/mL can not be used as 
markers of effectiveness of treatment with NA. As HBsAg 
disappearance is rarely observed with NA, the assessment 
of predictors for this outcome can be diffi cult to achieve 
and of little use from a clinical point of view.36-41
After one year of treatment with NA, the rates of un-
detectable HBV-DNA by PCR varied from 21%-67% in 
HBeAg-positive patients and 51%-90% in HBeAg-negative 
patients.29 For drugs with low genetic barrier to resistance, 
new cases of resistance can appear, probably, up to fi fth 
year of treatment.37,42 Consequently, predictors of main-
tained undetectable HBV-DNA levels are more useful if 
they can predict response at the end of fi ve years. On the 
other hand, the rate of undetectable HBV increases from 
81% to 87% when the duration of treatment with entecavir 
increases from 48 to 144 weeks.39 Therefore, predictors of 
maintained response with HBV-DNA of short-term treat-
ment can be useful for medications with higher genetic 
barrier to resistance. 
Predictors of response to PEG-IFN
A one-year treatment with PEG-IFN is considered one 
of the first-choice therapies for chronic hepatitis B.3-5 Its 
main advantage is having a finite treatment period, with 
absence of viral resistance, which allows other treatment 
options if there is no initial response. This therapy is 
better indicated for patients with a high chance of re-
sponse, as poor responders could be identified and treat-
ment with PEG-IFN should not be offered, or, in the 
absence of response throughout the treatment, the latter 
could be discontinued early. According to the experience 
with chronic hepatitis C, the combination of pretreat-
ment and on-treatment factors that predict a favorable 
response may allow the proposal of an individualized 
algorithm.43
Pretreatment predictors of response to PEG-IFN
There is a lower possibility for Asian patients to present 
HBeAg seroconversion in comparison to Caucasians, 
after receiving interferon.5 This observation is partially 
related to the duration of infection and to HBV geno-
type. In general, Asians acquire the infection in child-
hood and present a long phase of immune tolerance, 
which can cause less effective immunomodulation by 
treatment with interferon.44 The HBV genotype A, 
prevalent in Western Europe and America, is also as-
sociated with higher rates of response to treatment with 
interferon.45-47 In Asia and the Pacific regions, genotypes 
B and C are more prevalent and there is a controversy 
whether there is any difference regarding their response 
to interferon.15,45,46
Based on the results of well-designed studies, patients 
with good immunoreactivity tend to respond better to 
interferon. Immunoreactivity is represented by high lev-
els of ALT, low levels of HBV-DNA and high necroinflam-
matory activity at histological analysis. High pretreat-
ment ALT levels and low HBV-DNA levels are associated 
with higher rates of seroconversion with interferon 
treatment45,46,48,49 and also associated with responses to 
PEG-IFN alpha-2a in HBeAg-negative patients; ALT > 
5 – fold the upper limit of normality (ULN) was the 
most important predictor of combined response (ALT 
normalization, HBV-DNA suppression) in week 24 pos-
treatment.50 Quantitative HBsAg has recently become an 
important area of scientific interest. Many studies have 
suggested a correlation between HBsAg titer and the 
level of covalently closed circular DNA (cccDNA) and 
total intra-hepatic HBV-DNA.51,55 In a pilot-study con-
ducted with three arms, using three different regimens 
of PEG-IFN and lamivudine, in combination, patients 
with lower amounts of pre-treatment cccDNA presented 
higher sustained viral response (SVR).51,52 This observa-
tion seems logical, as lower levels of cccDNA must result 
in a stronger immune response. Additionally, quantita-
tive HBsAg, which has moderate correlation with the 
cccDNA, might provide a reasonable prediction of SVR 
at a level < 1,000 UI/mL.51 In a smaller study, conducted 
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in the Netherlands, pre-treatment HBsAg ≤ 2.25 log UI/mL 
turned out to be a predictor of HBsAg disappearance 
in patients receiving 48 weeks of PEG-IFN alpha-2a in 
combination with adefovir.53 However, in a large mul-
tinational multicentric study, the levels of HBsAg were 
not good predictors for seroconversion of HBeAg on the 
sixth and twelfth months after the end of the treatment 
(Table 1).54
Response predictors during treatment with PEG-IFN
Serum HBV-DNA
The response predictors during treatment with PEG-IFN 
must be analyzed depending on HBeAg result. In HBeAg-
positive patients treated with conventional interferon, 
the decrease in HBV-DNA during treatment was asso-
ciated with an improvement in clinical outcomes.8,65,66 
Currently, there is no consensus on the best moment 
and the best HBV-DNA cutoff to predict the response to 
treatment with PEG-IFN. In an European multicentric 
study, a decrease of 1 log (10-fold) in the levels of serum 
HBV-DNA in week 32 was a predictor of loss of HBeAg 
in patients treated with PEG-IFN alpha-2b, receiving 
monotherapy or a combined therapy with lamivudine.63 
In a multicentric, randomized, international controlled 
study, involving HBeAg-negative patients treated with 
PEG-IFN alpha-2a, 64% of the patients that attained a 
decrease in the HBV-DNA of < 400 copies/mL in week 
Table 1. Predictors of response to PEG-IFN reported 
in the medical literature. Recommendations based on 
small observational studies are cited between paren-
thesis; the other recommendations are based on the 
analysis of data derived from randomized and con-
trolled studies
Characteristic References
Ethnicity 
 Caucasians 5, 44
HBV Genotype  
 A 45-47
Level of ALT 
 High 45, 46, 48-50
HBV-DNA 
 Lower 45, 46, 48-50
Level of HBsAg 
 Lower 51-54
12 presented a combined sustained response (normal 
ALT -HBV-DNA < 20,000 copies/mL) in week 24 post-
treatment.57 Similarly, in another study with PEG-IFN 
alpha-2a, which included 40 patients that were previ-
ously non-responders to antiviral agents, 64% of those 
who attained HBV-DNA < 1,000 copies/mL in week 24 
presented SVR58. However, only a minority of patients 
can attain a good early control of viremia and a negative 
predictive value in week 12 or 24 of HBV-DNA for SVR 
was, approximately, of 70%.57,58 Another limitation to the 
use of HBV-DNA to predict the response to treatment is 
its failure to differentiate sustained responders from re-
lapsers. In a French study of 48 HBeAg-negative patients 
that received PEG-IFN alpha-2a due to chronic hepatitis 
B, the initial viral kinetics during the treatment of pa-
tients that presented viral suppression during therapy, 
but subsequently presented relapse after the end of the 
treatment, was almost identical to those with SVR.62 
One way to use the serum HBV-DNA as a predictor 
of response during treatment is to establish a withdrawal 
rule. In a combined post hoc analysis of two clinical trials 
using a combination of PEG-IFN alpha-2b and lamivu-
dine in HBeAg-positive patients with chronic hepatitis 
B,52,59 failure to decrease HBV-DNA to 10,000 copies/mL 
as early as in week 8 has a negative predictive value of 
92% for SVR.60 Based on the data of a randomized inter-
national study using PEG-IFN alpha-2a as monotherapy, 
a much higher cutoff, of 9 log copies/mL in week 24, was 
described as presenting a negative predictive value of 86% 
for sustained seroconversion of HBeAg.61 Whether or not 
the difference between these two studies is related to the 
nature of the two PEG-IFN requires further investigation. 
However, early kinetics of HBV-DNA can help the clinical 
decision-making of therapeutic withdrawal, particularly 
among patients that do not present good tolerance to the 
treatment. 
Quantitative HBsAg 
Many studies have shown that the elimination of the 
cccDNA and levels of HBsAg are associated with SVR 
during treatment with PEG-IFN. 
In a post hoc analysis of 47 patients after antiviral 
treatment, a lower level of cccDNA at the end of the 
treatment was associated with higher levels of SVR.59,67 
In 26 HBeAg-positive patients that completed the com-
bined treatment of PEG-IFN alpha-2b for 32 weeks and 
lamivudine for two years, a level of HBsAg < 1,500 UI/
mL presents 71% sensitivity and 84% specificity to pre-
dict SVR.51 In an international study with PEG-IFN al-
pha-2a, in HBeAg patients, a level < 10 UI/mL in week 
48 and decline during the treatment > 1 log UI/mL can 
predict a sustained disappearance of HBsAg three years 
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after the use of PEG-IFN alpha-2a, with or without the 
concomitant use of lamivudine.63 As serum levels of 
HBsAg can be correlated with cccDNA levels, monitor-
ing them has become a reasonable tool to predict the 
response to treatment with PEG-IFN during its course. 
In an international study with PEG-IFN alpha-2a in 
HBeAg-positive patients, a decrease in HBsAg levels 
< 1,500 UI/mL in week 12 or 24 might predict an in-
crease in the seroconversion rate of HBeAg (around 
50%).54 Similarly, 35% of the HBeAg-negative patients 
that attained levels of HBsAg of 1,500 UI/mL or less, in 
week 12 of treatment with PEG-IFN, presented elimina-
tion of the HBsAg four years later, after PEG-IFN alpha-
2a with or without lamivudine.64 Recently, there has 
been some controversy whether the absolute level of the 
HBsAg levels, or their decrease during treatment, are the 
best predictors of response in HBeAg-negative patients. 
In a French study by Moucari et al,62 it was verified that 
a decrease in serum HBsAg ≥ 1 log UI/mL in week 12 
was described as having a negative predictive value of 
97% for SVR after a 48-week treatment with PEG-IFN 
alpha-2a (serum HBV-DNA below detection 24 weeks 
postreatment, see Table 2).
Quantitative HBeAg 
The quantifi cation of HBeAg levels during treatment pro-
vides additional information to predict the chance of HBeAg 
seroconversion while on treatment with PEG-IFN alpha-2a. 
In an international study, among 271 HBeAg-positive pa-
tients treated with PEG-IFN alpha-2a as monotherapy high 
levels of HBeAg (> 100 Paul Ehrlich Institute Unit/mL) had 
a higher negative predictive value (96%) as compared to 
serum levels of HBV-DNA (86%).60 Therefore, high levels 
of HBeAg might be another criterion to predict non-re-
sponders. Unfortunately, the quantifi cation of HBeAg titers 
is yet to be standardized, which prevents its use in clinical 
practice. Moreover, this evaluation cannot be applied to 
HBsAg-positive patients. 
CONCLUSIONS
The prediction of the response to the treatment of chronic 
hepatitis B has become progressively more important as a 
factor of therapeutic individualization. Pretreatment pre-
dictors can help physicians selecting the best moment to 
initiate treatment, as well as the type of medication to be 
administered. The predictors of response used during treat-
ment, such as HBV-DNA and quantitative HBsAg, can po-
tentially guide the duration of treatment with PEG-IFN, as 
it is the case for the treatment of chronic hepatitis C. The use 
of PEG-IFN has the advantage of the limited time of treat-
ment and the absence of viral resistance, which allows the 
use of other antiviral agents in early non-responders. The 
correct use of these predictors may improve response and 
promote better clinical outcomes of treated chronic hepa-
titis B patients. 
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